An interview published by Qazinform News Agency has endocrinologist Diana Kuanyshbayeva making a point the influencer market would rather not hear: "peptide weight loss" is not a recognized medical term.

Peptides are short chains of amino acids, a category that already includes insulin, glucagon, GLP-1 and growth hormone. As Kuanyshbayeva puts it, the word itself tells you nothing about a drug's quality or effectiveness. It covers both approved medications that mimic gut hormones to suppress appetite and experimental substances such as BPC-157, for which she says evidence supporting weight loss is extremely limited.

Ozempic is already a peptide drug

The pitch online is that peptide injections are a newer generation than semaglutide and tirzepatide. They are not. Ozempic contains semaglutide, which acts on GLP-1 receptors, and Mounjaro contains tirzepatide, which targets GLP-1 and GIP. "The breakthrough in obesity treatment happened about five years ago, not today," Kuanyshbayeva said.

What is actually sold as something new, she said, may be familiar substances from unverified suppliers, experimental drugs such as retatrutide, or compounds never properly studied for weight management.

The candidate worth watching

Retatrutide, an Eli Lilly drug acting on three receptors rather than one or two, is the genuinely interesting item here. Phase 3 results announced in May 2026 reported participants on the highest studied dose losing an average of 28.3% of body weight over 80 weeks, and 30.3% after 104 weeks in an extension limited to participants with a baseline BMI of at least 35. Those numbers exceed earlier trials of existing drugs, though the article notes that comparisons across separate studies do not establish that one drug is superior. Gastrointestinal side effects are common and the drug is not approved.

What the FDA review did and did not do

In July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500 and MOTS-c, among others, for possible pharmacy compounding. Kuanyshbayeva is blunt that easing enforcement is not registration: none of the six peptides has been approved as a medicine, and none has established evidence supporting use as a weight-loss treatment.

Bottom line

The promotion is moving faster than the evidence, and the gap between "the future" and "safe today" is completed clinical research. That gap is where most of what is being sold online currently sits.